Your browser is no longer supported. Please, upgrade your browser.
Settings
NTLA [NASD]
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.36 Insider Own1.00% Shs Outstand73.71M Perf Week-10.70%
Market Cap8.18B Forward P/E- EPS next Y-3.85 Insider Trans-58.19% Shs Float67.02M Perf Month-25.66%
Income-228.80M PEG- EPS next Q-1.05 Inst Own82.40% Short Float5.18% Perf Quarter-42.85%
Sales26.80M P/S305.31 EPS this Y-13.80% Inst Trans1.02% Short Ratio4.65 Perf Half Y30.09%
Book/sh15.02 P/B6.73 EPS next Y0.60% ROA-26.90% Target Price174.56 Perf Year135.39%
Cash/sh9.86 P/C10.25 EPS next 5Y30.00% ROE-34.20% 52W Range39.81 - 202.73 Perf YTD85.72%
Dividend- P/FCF- EPS past 5Y-46.70% ROI- 52W High-50.17% Beta2.07
Dividend %- Quick Ratio8.40 Sales past 5Y57.20% Gross Margin- 52W Low153.78% ATR7.16
Employees312 Current Ratio8.40 Sales Q/Q-67.60% Oper. Margin- RSI (14)28.33 Volatility8.32% 6.02%
OptionableYes Debt/Eq0.00 EPS Q/Q-105.10% Profit Margin- Rel Volume1.26 Prev Close109.95
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume745.92K Price101.03
Recom2.10 SMA20-19.70% SMA50-22.61% SMA200-8.56% Volume938,827 Change-8.11%
Oct-05-21Initiated Guggenheim Buy $170
Sep-24-21Initiated Stifel Buy $173
Jun-28-21Reiterated H.C. Wainwright Buy $111 → $171
Jun-11-21Initiated H.C. Wainwright Buy $111
May-07-21Upgrade ROTH Capital Neutral → Buy $75 → $80
May-04-21Initiated RBC Capital Mkts Outperform $110
Mar-04-21Initiated JMP Securities Mkt Outperform $80
Dec-22-20Downgrade Robert W. Baird Outperform → Neutral $60
Oct-27-20Initiated Truist Buy $40
Oct-14-20Initiated Wells Fargo Overweight
Sep-18-20Initiated Goldman Buy $33
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Nov-22-21 07:30AM  
Nov-21-21 11:31AM  
Nov-12-21 09:34AM  
Nov-10-21 11:43AM  
10:48AM  
Nov-06-21 12:30PM  
Nov-05-21 07:30AM  
Nov-04-21 08:55AM  
07:30AM  
06:20AM  
Oct-28-21 03:26PM  
03:05PM  
07:30AM  
Oct-22-21 10:22AM  
Oct-21-21 07:30AM  
Oct-20-21 07:30AM  
Oct-19-21 09:25AM  
Oct-15-21 09:57AM  
Oct-13-21 07:01AM  
Oct-12-21 07:01PM  
11:58AM  
07:30AM  
Oct-06-21 08:29AM  
07:30AM  
Sep-27-21 11:58AM  
07:30AM  
Sep-17-21 01:35PM  
Sep-16-21 10:10AM  
07:30AM  
Aug-31-21 07:30AM  
Aug-26-21 12:45PM  
Aug-24-21 10:56AM  
Aug-17-21 10:21AM  
Aug-14-21 08:00AM  
Aug-12-21 08:31AM  
Aug-06-21 08:01PM  
Aug-05-21 03:59PM  
09:01AM  
08:45AM  
07:30AM  
Aug-02-21 08:52AM  
Jul-29-21 03:05PM  
07:30AM  
Jul-27-21 05:50PM  
Jul-16-21 11:02AM  
05:32AM  
Jul-15-21 08:19AM  
Jul-12-21 03:12PM  
Jul-11-21 07:01AM  
Jul-10-21 05:19AM  
Jul-09-21 04:04PM  
Jul-06-21 11:28AM  
Jul-04-21 07:49AM  
Jul-02-21 04:35PM  
04:01PM  
12:48PM  
Jul-01-21 06:56AM  
Jun-30-21 10:14PM  
04:20PM  
04:04PM  
03:30PM  
01:14PM  
12:14PM  
11:32AM  
08:46AM  
06:47AM  
06:42AM  
Jun-29-21 09:08PM  
11:20AM  
09:55AM  
09:34AM  
06:58AM  
05:15AM  
Jun-28-21 04:25PM  
04:12PM  
04:01PM  
02:36PM  
01:17PM  
12:22PM  
12:17PM  
11:09AM  
10:39AM  
10:02AM  
10:00AM  
09:15AM  
08:41AM  
08:39AM  
06:09AM  
05:34AM  
04:52AM  
04:06AM  
03:19AM  
Jun-27-21 07:25AM  
Jun-26-21 08:00PM  
01:07PM  
11:16AM  
Jun-25-21 04:45AM  
Jun-24-21 07:30AM  
Jun-22-21 07:00AM  
06:41AM  
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lebwohl DavidEVP, Chief Medical OfficerNov 05Option Exercise12.622,40030,28811,114Nov 09 06:08 PM
Lebwohl DavidEVP, Chief Medical OfficerNov 05Sale132.722,400318,5358,714Nov 09 06:08 PM
Lebwohl DavidEVP, Chief Medical OfficerOct 14Option Exercise12.622,40030,28811,114Oct 15 07:02 PM
Lebwohl DavidEVP, Chief Medical OfficerOct 14Sale128.442,400308,2498,714Oct 15 07:02 PM
Crowley John FDirectorOct 11Option Exercise18.832,50047,0754,594Oct 13 04:15 PM
Crowley John FDirectorOct 11Sale119.552,500298,8752,094Oct 13 04:15 PM
Crowley John FDirectorOct 05Option Exercise18.8310,000188,30012,094Oct 07 05:41 PM
Crowley John FDirectorOct 05Sale130.5410,0001,305,3912,094Oct 07 05:41 PM
Lebwohl DavidEVP, Chief Medical OfficerSep 24Option Exercise12.627,92399,9888,714Sep 27 04:15 PM
Lebwohl DavidEVP, Chief Medical OfficerSep 21Option Exercise12.622,40030,2883,191Sep 23 05:48 PM
Lebwohl DavidEVP, Chief Medical OfficerSep 21Sale149.812,400359,544791Sep 23 05:48 PM
Goddard GlennEVP, Chief Financial OfficerSep 07Option Exercise14.583,48250,7683,482Sep 09 05:38 PM
Goddard GlennEVP, Chief Financial OfficerSep 07Sale180.123,482627,1780Sep 09 05:38 PM
LEONARD JOHN MPresident and CEOSep 01Option Exercise21.6244,735967,000764,040Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOSep 01Sale170.0044,7357,604,950719,305Sep 01 08:21 PM
Goddard GlennEVP, Chief Financial OfficerAug 31Option Exercise18.9324,800469,37424,800Sep 01 07:30 PM
LEONARD JOHN MPresident and CEOAug 31Option Exercise14.5837,833551,605757,138Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOAug 31Sale155.0037,8335,864,115719,305Sep 01 08:21 PM
Goddard GlennEVP, Chief Financial OfficerAug 31Sale160.2224,8003,973,4560Sep 01 07:30 PM
Goddard GlennEVP, Chief Financial OfficerAug 30Option Exercise19.275,200100,2045,200Sep 01 07:30 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 30Option Exercise12.622,40030,2883,191Sep 01 07:32 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 30Option Exercise14.0197,0001,359,30099,391Sep 01 07:34 PM
LEONARD JOHN MPresident and CEOAug 30Option Exercise14.2338,804552,031758,109Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOAug 30Sale155.9538,8046,051,353719,305Sep 01 08:21 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 30Sale154.8397,00015,018,0542,391Sep 01 07:34 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 30Sale158.042,400379,300791Sep 01 07:32 PM
Goddard GlennEVP, Chief Financial OfficerAug 30Sale155.785,200810,0820Sep 01 07:30 PM
LEONARD JOHN MPresident and CEOAug 23Option Exercise13.4027,139363,663746,444Aug 25 04:14 PM
LEONARD JOHN MPresident and CEOAug 23Sale152.0127,1394,125,416719,305Aug 25 04:14 PM
LEONARD JOHN MPresident and CEOAug 19Option Exercise13.4022,682303,939741,987Aug 20 06:14 PM
LEONARD JOHN MPresident and CEOAug 19Sale151.2822,6823,431,398719,305Aug 20 06:14 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 09Option Exercise12.622,40030,2883,191Aug 11 04:50 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 09Sale164.052,400393,720791Aug 11 04:50 PM
Goddard GlennEVP, Chief Financial OfficerAug 05Option Exercise19.2720,000385,40020,000Aug 06 06:17 PM
Goddard GlennEVP, Chief Financial OfficerAug 05Sale151.0520,0003,021,0560Aug 06 06:17 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 04Option Exercise13.4026,000348,40028,391Aug 06 06:19 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 04Sale138.2426,0003,594,3572,391Aug 06 06:19 PM
FORMELA JEAN FRANCOISDirectorJun 28Sale132.73553,37673,448,87910,000Jun 29 09:48 AM
FORMELA JEAN FRANCOISDirectorJun 14Sale87.37170,77914,921,294563,376Jun 15 09:51 AM
FORMELA JEAN FRANCOISDirectorJun 11Sale85.2330,9462,637,480734,155Jun 15 09:51 AM
FORMELA JEAN FRANCOISDirectorApr 29Sale85.434,513385,546765,101Apr 30 08:55 PM
FORMELA JEAN FRANCOISDirectorApr 28Sale85.56131,92611,287,893769,614Apr 28 07:51 PM
FORMELA JEAN FRANCOISDirectorApr 27Sale86.22210,23018,125,992901,540Apr 28 07:51 PM
FORMELA JEAN FRANCOISDirectorApr 26Sale84.9380668,4541,111,770Apr 28 07:51 PM
LEONARD JOHN MPresident and CEOApr 13Option Exercise11.1625,937289,506719,305Apr 15 08:50 PM
DORSA CAROLINEDirectorApr 05Option Exercise6.407,50048,00012,910Apr 06 06:09 PM
FORMELA JEAN FRANCOISDirectorApr 05Sale84.9880067,9841,112,576Apr 07 02:14 PM
DORSA CAROLINEDirectorApr 05Sale82.197,500616,4055,410Apr 06 06:09 PM
Rivera Jose EEVP, General CounselApr 01Option Exercise12.5197,0011,213,537178,077Apr 02 08:42 PM
LEONARD JOHN MPresident and CEOApr 01Option Exercise14.1571,0411,005,049707,263Apr 02 08:46 PM
LEONARD JOHN MPresident and CEOApr 01Sale83.6438,2093,195,661681,222Apr 02 08:46 PM
Rivera Jose EEVP, General CounselApr 01Sale82.4650,4554,160,559131,032Apr 02 08:42 PM
FORMELA JEAN FRANCOISDirectorFeb 26Sale60.29501,94530,262,7161,113,376Mar 01 01:59 PM
LEONARD JOHN MPresident and CEOFeb 09Option Exercise6.8356,718387,384688,579Feb 09 08:36 PM
Rivera Jose EEVP, General CounselFeb 09Option Exercise18.3021,000384,195129,409Feb 09 08:38 PM
Rivera Jose EEVP, General CounselFeb 09Sale75.0011,489861,675117,920Feb 09 08:38 PM
LEONARD JOHN MPresident and CEOFeb 09Sale75.0028,0432,103,225660,536Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 05Option Exercise13.4040,000536,000654,803Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 05Sale67.6622,9421,552,185631,861Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 03Option Exercise17.68117,0602,069,793651,661Feb 03 09:39 PM
LEONARD JOHN MPresident and CEOFeb 03Sale72.5467,8564,922,490584,601Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Option Exercise9.68109,0001,054,620121,686Feb 03 09:38 PM
LEONARD JOHN MPresident and CEOFeb 01Option Exercise13.69200,0002,737,600598,814Feb 03 09:39 PM
LEONARD JOHN MPresident and CEOFeb 01Sale64.00109,8897,032,905523,853Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Sale63.9954,6593,497,90288,686Feb 03 09:38 PM
Cohen Fred EDirectorJan 20Option Exercise13.7820,000275,60030,000Jan 22 04:22 PM
LEONARD JOHN MPresident and CEOJan 05Sale55.866,239348,511475,488Jan 05 09:24 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerJan 05Sale55.861,37776,91916,656Jan 05 08:58 PM
Rivera Jose EEVP, General CounselJan 05Sale55.862,078116,07751,990Jan 05 08:55 PM
LEONARD JOHN MPresident and CEODec 31Option Exercise0.0014,3750481,727Jan 05 09:24 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 31Option Exercise0.004,792018,033Jan 05 08:58 PM
Rivera Jose EEVP, General CounselDec 31Option Exercise0.004,792054,068Jan 05 08:55 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 30Option Exercise13.481,50020,22012,673Jan 04 09:03 PM
KARSEN PERRY ADirectorDec 17Option Exercise18.4588,7641,637,84293,764Dec 18 04:29 PM
KARSEN PERRY ADirectorDec 17Sale53.5588,7644,753,6805,000Dec 18 04:29 PM